ライフサイエンスコーパス: be weighed against

1 for calcineurin signaling in the heart will be weighed against a growing body of literature suggesti

2 l benefits of GP IIb/IIIa inhibitor use must be weighed against an increased risk of bleeding.

3 n injury, and neurodevelopmental delays must be weighed against an increased risk of unscheduled, pre

4 ich a currently available, known option must be weighed against an unknown alternative option.

5 s the reduction in occlusive events needs to be weighed against any increase in major bleeds.

6 ative regional anesthetic techniques need to be weighed against any potential risks and this should b

7 de-offs in which the health of the many must be weighed against burdens imposed on individuals.

8 erns about potential adverse effects need to be weighed against concerns about possible death from un

9 apy, the therapeutic benefits and risks must be weighed against consideration of the disease threat.

10 ol the precision of stimulus encoding, which is weighed against contextual information when making de

11 al utility of fMRI is influenced by and must be weighed against cost and accessibility factors.

12 ce contamination from aerosol box use should be weighed against delayed time to complete intubation,

13 However, these advantages must be weighed against differences in cost and test accuracy

14 ssible risk of a SARS-CoV-2 infection had to be weighed against each other.

15 These potential benefits, however, should be weighed against expected adverse effects on risk of g

16 eyond an early stage, although benefits must be weighed against harms to others on the waiting list.

17 The benefits of a candidate control signal are weighed against its costs (e.g., opportunity costs).

18 gh the advantages of cell-based therapy must be weighed against its added cost and complexity.

19 d possible adverse effects of surgery should be weighed against its benefits, bariatric surgery and,

20 e beneficial effect of cyclophosphamide must be weighed against its considerable toxic effects.

21 k reduction for each of these therapies must be weighed against its cost and potential adverse events

22 efits of any revascularization strategy must be weighed against its initial risks.

23 gs in the longer term, but its efficacy must be weighed against its side effect profile.

24 f IORAT over the other two procedures should be weighed against its significant association with post

25 lity advantages of the polarized device must be weighed against its substantially higher cost.

26 The effect of anastrozole on bone should be weighed against its superior efficacy and better tole

27 Nonmaleficence ("do no harm") must be weighed against maternal autonomy.

28 e ineligible for LVAD trial inclusion should be weighed against medical management, more consideratio

29 ol's quantitative assessment of CKD risk may be weighed against other considerations when planning ma

30 ger low-risk patients, valve durability must be weighed against other patient factors such as life ex

31 The reduction in vasomotor symptoms must be weighed against other risks and benefits of treatment

32 Therefore, culture-based prophylaxis must be weighed against other strategies that could reduce po

33 ; medication-associated dementia risk should be weighed against other therapies such as cognitive beh

34 make our result acutely policy relevant, to be weighed against possible ozone increases.

35 gional anesthesia improves safety but should be weighed against possible reductions in speed of onset

36 and low prevalence of early seizures should be weighed against potential acute risks of antiseizure

37 These benefits must be weighed against potential adverse effects, including

38 etal complications with zoledronic acid must be weighed against potential adverse effects.

39 ic cigarettes to an individual smoker should be weighed against potential harm to the population of i

40 n is used, potential efficiency gains should be weighed against potential loss of power to arrive at

41 benefits of free samples in dermatology must be weighed against potential negative effects on prescri

42 fit of complex prognostic evaluations should be weighed against potential patient discomfort and cost

43 The benefits from regional RT should be weighed against potential radiation-associated toxic

44 ntages of regular coffee consumption have to be weighed against potential risks (which are mostly rel

45 benefits of hormone replacement therapy must be weighed against potential risks of thrombotic events,

46 n this anthracycline-exposed population must be weighed against potential side effects from ACE inhib

47 r disorder; however, potential benefits must be weighed against potential side effects, including ras

48 se prevention in psychiatric conditions must be weighed against potential teratogenic effects.

49 of anticipating recurrence detection should be weighed against psychological burden and radiologic e

50 further accelerate time-to-antibiotics must be weighed against risks of overtreatment.

51 fferences among pediatric recipients, should be weighed against risks of prolonged waitlist time in r

52 and a reduced risk of urinary problems must be weighed against sexual side effects and the increased

53 , the benefits of a more durable repair must be weighed against such risks as vaginal mesh extrusion

54 , downstream harms from follow-up tests must be weighed against surveillance benefits when determinin

55 matory lung diseases and PI3Kgamma in asthma are weighed against the consequences of manipulating key

56 The value of this benefit must be weighed against the added cost of ultrasonographic gu

57 pandemic, where reducing transmission had to be weighed against the adverse effects on young children

58 k to the fetus of the imaging procedure must be weighed against the benefit to the mother of early an

59 tAML risks should be weighed against the benefits of chemotherapy, particu

60 sception after vaccination, a risk that must be weighed against the benefits of preventing rotavirus-

61 n clinical importance, and the findings must be weighed against the benefits of treating maternal dep

62 This elevated risk should be weighed against the benefits of vaccination.

63 l procedures or experimental therapy have to be weighed against the chance of improvement and the pot

64 of complications during surgical repair must be weighed against the chance that the retinal detachmen

65 These benefits must be weighed against the cost of the vaccines in future an

66 roader impacts of bioenergy expansion should be weighed against the costs and benefits of re/afforest

67 of generating such sequences, however, must be weighed against the costs of further evolution by seq

68 ood safety prevention and control rules must be weighed against the estimated benefits of reducing fo

69 tional lowering of intraocular pressure must be weighed against the following potential disadvantages

70 d an early stage, although any benefits must be weighed against the harms to others on the waiting li

71 These subjective benefits need to be weighed against the high costs of the drugs to patien

72 , the benefits of once weekly dosing need to be weighed against the higher risks of cytopenias and gr

73 This risk must be weighed against the important role of PIs in modern A

74 The risk of prophylactic therapy must be weighed against the incidence of PCP in the patient p

75 icacy data for escalated-dose treatment must be weighed against the increase in acute and late toxici

76 ascular benefits of intensive therapy should be weighed against the increase in total and cardiovascu

77 The benefits of mTOR inhibitors must be weighed against the increased risk of adverse events

78 the benefit of antithrombotic therapies must be weighed against the increased risk of bleeding, which

79 breast cancer and vertebral fracture should be weighed against the increased risks of venous thrombo

80 fit of decreasing delays in discharge should be weighed against the increased total duration of criti

81 cision to use closed incision NPWT must also be weighed against the increases in skin blistering and

82 ty of time-to-deterioration endpoints should be weighed against the information that they add to the

83 These must be weighed against the irreversibility of the decision,

84 This benefit must be weighed against the known side-effect profile of thes

85 e effects of inhaled corticosteroids need to be weighed against the large and well established benefi

86 , the potential for harm from screening must be weighed against the likelihood of benefit, especially

87 anges observed after interferon therapy must be weighed against the limitations of liver biopsy and t

88 he potential efficacy of trabeculectomy must be weighed against the long-term risk of complications,

89 This must be weighed against the lower stoma prevalence in this gr

90 Benefits of school reopening must be weighed against the morbidity and mortality risks and

91 with microbubbles, but these advantages must be weighed against the need to use higher bubble concent

92 agents are expensive, but annual costs must be weighed against the personal and societal expense of

93 These advantages, however, must be weighed against the possibility of increased rates of

94 ent interruptions of enteral feeding need to be weighed against the possible benefits derived from th

95 latelet or anticoagulant drugs should always be weighed against the possible prothrombotic effects as

96 Radiation exposure should be weighed against the potential benefit of metastasis-d

97 sed blood transfusion requirements that must be weighed against the potential clinical and economic i

98 The benefits must be weighed against the potential detrimental effects.

99 ntial benefits of these interventions cannot be weighed against the potential for adverse effects owi

100 The improvement in bleb survival must be weighed against the potential for complications relat

101 , current, and former beryllium workers must be weighed against the potential for employment and insu

102 may have detrimental effects, which need to be weighed against the potential gains in muscle growth

103 lung cancer mortality, but its benefits must be weighed against the potential harms of unnecessary pr

104 rawing steroids the risk of rejection should be weighed against the potential metabolic advantages.

105 e elimination of aortic cross-clamping) must be weighed against the potential risk for later adverse

106 each individual's risk of recurrence should be weighed against the potential risks of adjuvant thera

107 The potential benefit of iNO therapy must be weighed against the potential risks of inactivating s

108 ncremental increase in benefit with BMT must be weighed against the potential serious harm and death

109 of introducing such a staffing model need to be weighed against the potential total savings generated

110 owever, the benefits of pain management must be weighed against the potentially lethal risk of opioid

111 r, the advantages of OW fertilization should be weighed against the potentially negative environmenta

112 , any reduction in late effects will have to be weighed against the probability of survival if altern

113 These findings need to be weighed against the probable benefits of long-term tr

114 sk of diabetes, but this adverse effect must be weighed against the proven benefits of beta-blockers

115 state cancer deaths, and PSA failures should be weighed against the risk of adverse events and the im

116 and long term teratogenicity, however, must be weighed against the risk of CMV disease in the recipi

117 Appropriate prophylaxis should be weighed against the risk of complications and offered

118 , the potential benefits of treatment should be weighed against the risk of drug-resistant mutations

119 apies can treat CGD-IBD, their benefits must be weighed against the risk of infection.

120 Aemia and immunosuppression reduction should be weighed against the risk of occurrence of rejection,

121 The benefit of natalizumab will need to be weighed against the risk of serious adverse events, i

122 dical management strategies of diabetes must be weighed against the risk of serious adverse events.

123 nt but its prolonged duration of action must be weighed against the risk of side effects associated w

124 The risk of tumor transmission should be weighed against the risk of the patient dying on the

125 ific rationale for benefit exists and should be weighed against the risks (adverse events, antibiotic

126 be cost-effective, but the benefits need to be weighed against the risks associated with increased a

127 enefits of defining coronary anatomy have to be weighed against the risks of additional delay before

128 ial benefits of additional macrolides should be weighed against the risks of adverse effects and anti

129 munosuppression and risk of malignancy, must be weighed against the risks of HSCT.

130 he benefits of such a strategy would need to be weighed against the risks of leaving young children u

131 otential benefit of achieving tolerance must be weighed against the risks of rejection therapy in pat

132 ed complications with mechanical valves must be weighed against the risks of structural deterioration

133 The benefits of preventing VTE must be weighed against the risks.

134 The benefits need to be weighed against the risks.

135 lar diagnoses and clinical situations should be weighed against the specific risks associated with th

136 rgeting Th2-type cytokines, however, need to be weighed against the toxicities associated with inhibi

137 hogens; however, in some cases, this benefit is weighed against the cost of potential self recognitio

138 nstrated benefits of ARNi and SGLT2is should be weighed against their high prices in payer and policy

139 The higher costs of TM/HBPC should be weighed against these benefits.

140 he benefits of GnRH agonist treatment should be weighed against these potential risks.

141 ndary end points, any potential benefit must be weighed against toxicity.